Forge Biologics to Present and Participate at Upcoming Investor Conferences
Ohio Pen/10194062

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that company leadership members will be making presentations and taking one-on-one meetings at three upcoming investor relations conferences.

Jefferies Cell & Genetic Medicine Summit
Friday, September 30, 10:00-10:25 a.m. ET
Presenter: Christina Perry, Senior Vice President and Head, Finance & Investor Relations
Webcast Link: https://wsw.com/webcast/jeff259/forge/2001825

Chardan Genetic Medicines Conference
Monday, October 3, 2:00-2:25 p.m. ET
Presenter: Timothy J. Miller, CEO, President and Co-Founder
Webcast Link: https://wsw.com/webcast/chard14/forge/2063205

More on Ohio Pen

• InventHelp Inventor Develops Improved Design for a Cake Pan (CCT-4737)
• Mayor Horrigan Appoints Tammy Tucker as Akrons First Director of Diversity, Equity, and Inclusion
• City of Akron Responds to Racial Equity and Social Justice Taskforce Recommendations
• Cold Atom Physics Experiments Controlled by ADwin
• Play time for edge computing is over—full scale deployments in 2023, predicts IOTech

SVB Securities Biopharma Private Company Connect
Wednesday, October 26, 2022
Company executives will hold virtual one-on-one meetings with investors during the event. Meetings with the management team may be requested through SVB Securities.

Forge's presentations will be available for 90 days following each event by visiting the Company's Events website at https://www.forgebiologics.com/news/#events.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge's mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge's 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.

More on Ohio Pen

• The warm comfort of Sloppy Joes slides back into White Castle just in time for winter's arrival
• Babcock & Wilcox and Chart Industries to Collaborate on Hydrogen Innovation Utilizing B&W's BrightLoopTM Technology
• Earthfirst® Films Announces Leadership Changes USA - English USA - English
• Navidea Biopharmaceuticals Files Appeal in CRG Case
• Entertainer Sidow Sobrino Celebrates his 47th Birthday on December 1st

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Investor Relations
Christina Perry
Senior Vice President, Head of Finance and Investor Relations
Investors@forgebiologics.com

---

Show All News | Report Violation